Retatrutide
Eli Lilly
Mentioned 2 times across 2 shows · first heard Mar 2026 on The Dylan Gemelli Podcast.
The general take
David Friedberg is enthusiastic about retatrutide's phase three clinical trial results from Lilly, calling them "pretty amazing." He notes it's a step beyond trisepatide, Lilly's current dual agonist product, by adding additional receptor binding capabilities. The limited quote suggests he sees real promise in the data, though the full scope of his assessment isn't captured here.
About
Retatrutide The GLP-1/GIP/Glucagon Triple-Agonist Guide to Weight Loss, Appetite Control & Metabolic Reset What if one weekly shot could turn down “food noise,” help you stop comfortably at two-thirds of a plate, and move stubborn metabolic risk in the right direction? Retatrutide —a next-generation GLP-1/GIP/glucagon triple-agonist —is the most ambitious incretin therapy yet. In clear, non-hyped language, this guide explains what it is, how it works, who it’s for, and how to use it responsibly —from first dose to long-term maintenance. Inside you’ll learn: The science in plain English: why combining GLP-1, GIP, and glucagon can produce larger, steadier weight loss and a different day-to-day appetite feel. What the trials showed: including striking liver-fat and A1C changes—and what questions phase-3 outcomes will answer next.
Who said what
David Friedberg👍 Recommends
…discussing retatrutide peptide medication clinical trial results
“The coverage is coming out of this phase three clinical trial data release that Lilly put out last month. So, everyone's going crazy over the data, which continues to show pretty amazing results. So, unlike trisepatide, which is kind of Lilly's main product today, which is a dual agonist, it's got two peptides in it that bind to different receptors, the GLP-1, the GIP receptor. This other one now also binds to glucagon, which is a third receptor.”
All-In with Chamath, Jason, Sacks & Friedberg — OpenAI Misses Targets, Codex vs Claude, Elon vs Sam Trial, Big Hyperscaler Beats, Peptide Crazeat 59:15
Dylan Gemelli👍 Recommends
…triple GLP-1/GIP/glucagon receptor agonist for metabolic optimization
“Red atrutide smokes everything. It is insane. Right. That one is incredible, but it's right now it's gone from almost all the sites. It's incredible compounds. I have seen tremendous benefits from myself and other people I've worked with, whether you are lean or overweight, you'll see benefits with Retta.”
The Dylan Gemelli Podcast — Episode #103 Featuring Shawn Wells! The MOST TRUSTED Name in Supplements! ASTONISHING INSIGHT from the wide world of supplements! Also discussions on Peptides, SARMS, Scams and MORE!at 43:17
Listener reviews
Bought Retatrutide after hearing about it? Tell everyone how it went.
